{Reference Type}: Journal Article
{Title}: Montelukast and Coronavirus Disease 2019: A Scoping Review.
{Author}: Sharifinejad N;Sharafian S;Salekmoghadam S;Tavakol M;Qorbani M;
{Journal}: Iran J Allergy Asthma Immunol
{Volume}: 20
{Issue}: 4
{Year}: Aug 2021 7
{Factor}: 1.57
{Abstract}: Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness.